New Treatment Possibilities for patients with recurrent or primary advanced endometrial cancer
Listen to Mansoor Raza Mirza discussing the ENGOT-EN6 RUBY study. The study focused on the effectiveness of the drug dostarlimab combined with carboplatin-paclitaxel compared to a placebo for patients with recurrent or primary advanced endometrial cancer. The results showed significant benefits, especially for patients with specific molecular profiles, such as p53 mutations. These findings have implications for tailoring treatment in the future and determining which patients may benefit from immune checkpoint inhibitors.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.